Daniel L. Clarke‐pearson
#158,433
Most Influential Person Now
Daniel L. Clarke‐pearson's AcademicInfluence.com Rankings
Daniel L. Clarke‐pearsonphilosophy Degrees
Philosophy
#9037
World Rank
#12532
Historical Rank
Logic
#6039
World Rank
#7517
Historical Rank
Download Badge
Philosophy
Daniel L. Clarke‐pearson's Degrees
- Doctorate Medicine University of North Carolina at Chapel Hill
Why Is Daniel L. Clarke‐pearson Influential?
(Suggest an Edit or Addition)Daniel L. Clarke‐pearson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer (1996) (2311)
- Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. (2003) (1933)
- Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. (1999) (1664)
- Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. (1999) (1410)
- Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. (1996) (1172)
- American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. (2007) (953)
- Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. (1990) (814)
- Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. (2003) (560)
- Overexpression and mutation of p53 in epithelial ovarian cancer. (1991) (491)
- Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. (2005) (405)
- Clinical practice. Screening for ovarian cancer. (2009) (358)
- Secondary surgical cytoreduction for advanced ovarian carcinoma. (2004) (319)
- Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. (2006) (249)
- Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. (1997) (246)
- Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. (2007) (240)
- Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. (1991) (238)
- Overexpression and mutation of p53 in endometrial carcinoma. (1992) (231)
- Elevation of multiple serum markers in patients with stage I ovarian cancer. (1993) (207)
- Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. (1993) (184)
- Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. (1999) (177)
- The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. (2000) (176)
- Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). (1996) (168)
- Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. (1985) (164)
- Multivariable analysis of DNA ploidy, p53, and HER‐2/neu as prognostic factors in endometrial cancer (1994) (160)
- Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. (1991) (160)
- Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. (1992) (135)
- Prevention of Postoperative Venous Thromboembolism by External Pneumatic Calf Compression in Patients With Gynecologic Malignancy (1984) (133)
- An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. (1996) (131)
- The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. (2007) (130)
- Complications of Hysterectomy (2013) (124)
- Prevention of venous thromboembolism. European Consensus Statement, 1-5 November 1991, developed at Oakley Court Hotel, Windsor, UK. (1992) (124)
- The role of PET scanning in the detection of recurrent cervical cancer. (2003) (124)
- A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. (1993) (124)
- Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. (2006) (122)
- A Controlled Trial of Two Low-Dose Heparin Regimens for the Prevention of Postoperative Deep Vein Thrombosis (1990) (112)
- Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. (1995) (111)
- Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroid tumors in premenopausal women: a decision analysis. (2015) (108)
- Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. (2005) (101)
- Management of stage IA carcinoma of the cervix. (1985) (99)
- Pelvic exenteration: factors associated with major surgical morbidity. (1989) (99)
- A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. (2002) (98)
- A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. (2008) (96)
- Sites of failure and times to failure in carcinoma of the vulva treated conservatively: a Gynecologic Oncology Group study. (1996) (95)
- Outcomes in surgical stage I uterine papillary serous carcinoma. (2007) (93)
- Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology (2006) (92)
- Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer: II. Relationship between receptor expression and response to epidermal growth factor (1991) (91)
- Epithelial Ovarian Tumors of Low Malignant Potential (1991) (88)
- Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. (1987) (87)
- Thromboembolism Complicating Surgery for Cervical and Uterine Malignancy: Incidence, Risk Factors, and Prophylaxis (1983) (86)
- Pneumatic Compression Versus Low Molecular Weight Heparin in Gynecologic Oncology Surgery: A Randomized Trial (2001) (85)
- Recurrent gestational trophoblastic disease. Experience of the southeastern regional trophoblastic disease center (1990) (84)
- Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. (1991) (84)
- p53 overexpression in advanced-stage endometrial adenocarcinoma. (1996) (82)
- Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. (2003) (81)
- Comprehensive Restaging Laparotomy in Women With Apparent Early Ovarian Carcinoma (1992) (80)
- Role of Computed Axial Tomography of the Chest in Staging Patients With Nonmetastatic Gestational Trophoblastic Disease (1986) (80)
- Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery. (1992) (78)
- Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. (2003) (77)
- Gestational trophoblastic disease metastatic to the central nervous system. (1995) (73)
- Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. (1994) (72)
- Epidermal growth factor receptor expression in normal and malignant endometrium. (1989) (71)
- The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. (2007) (69)
- Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. (2003) (69)
- Venous Thromboembolism Prophylaxis: Patients at High Risk to Fail Intermittent Pneumatic Compression (2003) (67)
- 5-day methotrexate for women with metastatic gestational trophoblastic disease. (1994) (67)
- Translational Studies of Phenotypic Probes for the Mononuclear Phagocyte System and Liposomal Pharmacology (2013) (66)
- Stereotactic body radiotherapy (SBRT): Technological innovation and application in gynecologic oncology. (2011) (65)
- A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. (1997) (64)
- Malignant Potential of Gestational Trophoblastic Disease at the Extreme Ages of Reproductive Life (1984) (63)
- The Negative Prognostic Implications of Thrombocytosis in Women With Stage IB Cervical Cancer (1994) (62)
- The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. (1991) (59)
- Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. (2007) (56)
- Cost‐Effectiveness of Deep Venous Thrombosis Prophylaxis in Gynecologic Oncology Surgery (2000) (55)
- Relationship Between Race and interval to Treatment in Endometrial Cancer (1995) (54)
- Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. (1990) (53)
- Prevention of Venous Thromboembolic Events After Gynecologic Surgery (2012) (53)
- The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. (1990) (52)
- Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. (2001) (52)
- Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. (2005) (51)
- OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. (1993) (51)
- Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. (1993) (51)
- Cryosurgery in the Management of Cervical Intraepithelial Neoplasia (1984) (50)
- High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. (1990) (50)
- Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. (1997) (50)
- Alternating weekly chemotherapy with etoposide‐methotrexatedactinomycin/cyclophosphamide‐vincristine for high‐risk gestational trophoblastic disease (1994) (50)
- Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. (2001) (48)
- Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission. Correlation with surgical-pathologic findings. (1986) (48)
- Predictors of clinical outcomes in the laparoscopic management of adnexal masses. (2003) (47)
- Computed Tomography in Evaluation of Extrapelvic Lymphadenopathy in Carcinoma of the Cervix (1985) (47)
- Metastatic Gestational Trophoblastic Disease: Prognostic Factors in Previously Untreated Patients (1988) (47)
- A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma (2003) (46)
- Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. (1985) (45)
- Topical application of WR‐2721 to prevent radiation‐induced proctosigmoiditis. A phase I/II trial (1992) (44)
- Long-term effects on bladder function following radical hysterectomy with and without postoperative radiation. (1987) (44)
- Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroids: an updated decision analysis following the 2014 Food and Drug Administration safety communications (2017) (43)
- Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery. (2004) (43)
- Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity (2006) (43)
- Long and short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery: comparison of flap-specific complications. (1995) (42)
- Evaluation of Prognostic Factors and Staging in Gestational Trophoblastic Tumor (1994) (42)
- Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. (1989) (40)
- Radical Hysterectomy in Obese Women (1992) (40)
- Predictors of Clinical Outcomes in the Laparoscopic Management of Adnexal Masses (2003) (37)
- Comparison of combination therapy with paclitaxel Taxol® and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study (1996) (37)
- Defining practice patterns in gynecologic oncology to prevent pulmonary embolism and deep venous thrombosis. (2007) (37)
- U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women? (2016) (36)
- Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases. (1985) (36)
- Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. (1984) (36)
- Intestinal obstruction in patients with ovarian cancer. Variables associated with surgical complications and survival. (1988) (35)
- Prevention of venous thromboembolism in gynecologic oncology surgery. (2017) (35)
- The limited utility of currently available venous thromboembolism risk assessment tools in gynecological oncology patients. (2016) (35)
- Venous Thromboembolism in Minimally Invasive Compared With Open Hysterectomy for Endometrial Cancer (2016) (35)
- Preoperative Coagulation Testing on a Gynecologic Oncology Service (1994) (34)
- Radical hysterectomy as therapy for early carcinoma of the cervix (1986) (34)
- Complications of Low-Dose Heparin Prophylaxis in Gynecologic Oncology Surgery (1984) (34)
- Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer (2007) (34)
- High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients. (2007) (34)
- Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. (1993) (33)
- Phase III study of intraperitoneal cisplatin-intravenous cyclophosphamide versus intravenous cisplatin-intravenous cyclophosphamide in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG Intergroup study (1996) (33)
- Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery (2004) (31)
- Pneumatosis Intestinalis Associated With Enteral Feeding by Catheter Jejunostomy (1985) (31)
- Peritoneal Washings After Power Morcellation in Laparoscopic Myomectomy: A Pilot Study. (2015) (31)
- Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression. (2003) (30)
- Prevention of superficial wound separation with subcutaneous retention sutures. (1993) (30)
- Ploidy analysis of epithelial ovarian cancers using image cytometry. (1992) (29)
- Uterine Morcellation at the Time of Hysterectomy: Techniques, Risks, and Recommendations (2014) (29)
- Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. (1987) (28)
- Preference and Compliance in Postoperative Thromboembolism Prophylaxis Among Gynecologic Oncology Patients (2002) (28)
- Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial. (2004) (28)
- Phase I/II trial of intravenous Doxil® and whole abdomen hyperthermia in patients with refractory ovarian cancer (2005) (27)
- A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies (1996) (27)
- Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity. (2005) (25)
- Percutaneous nephrostomy in gynecologic oncology patients. (1988) (25)
- Stage I small cell carcinoma of the vulva treated with vulvectomy, lymphadenectomy, and adjuvant chemotherapy (1991) (23)
- Results of outpatient therapy of cervical intraepithelial neoplasia. (1981) (22)
- Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer (2016) (22)
- Absorbable synthetic mesh (polyglactin 910) for the formation of a pelvic "lid" after radical pelvic resection. (1988) (22)
- Gynecologic, Obstetric, and Related Surgery (1997) (22)
- Renal Metastases of Gestational Trophoblastic Disease: A Report of Eight Cases (1988) (21)
- Diagnosis of Deep Venous Thrombosis in Obstetrics and Gynecology by Impedance Phlebography (1981) (20)
- Obesity is associated with worse quality of life in women with gynecologic malignancies: An opportunity to improve patient‐centered outcomes (2015) (20)
- American Society of Clinical Oncology 2007 Clinical Practice Guideline Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. (2007) (20)
- Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma (2006) (20)
- The clinical significance of blood transfusion at the time of radical hysterectomy. (1991) (19)
- VILLOGLANDULAR ADENOCARCINOMA OF THE CERVIX: A CASE REPORT (1995) (18)
- Prevention of venous thromboembolism in gynecologic surgery patients (1993) (17)
- Cost-effectiveness of treatment of early stage endometrial cancer. (1999) (17)
- A VP16-213- and cisplatin-containing regimen for treatment of refractory ovarian germ cell malignancies. (1984) (17)
- Cost benefit of intermittent pneumatic compression for venous thromboembolism prophylaxis in general surgery. (2008) (15)
- Cost-Effectiveness of Laparoscopic Hysterectomy With Morcellation Compared With Abdominal Hysterectomy for Presumed Myomas. (2016) (15)
- A statement on abortion by 100 professors of obstetrics: 40 years later. (2013) (15)
- An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. (2016) (15)
- Surgical training in gynecologic oncology: Past, present, future. (2020) (14)
- Preoperative evaluation and postoperative management (2006) (14)
- Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues. (1989) (14)
- Thromboembolism in patients with Gyn tumors: risk factors, natural history, and prophylaxis. (1989) (14)
- Absorbable synthetic mesh (910-polyglactin) intestinal sling to reduce radiation-induced small bowel injury in patients with pelvic malignancies. (1988) (14)
- The abnormal pap smear—what to do next? (1981) (13)
- Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. (1995) (13)
- Increased serum levels of macrophage colony‐stimulating factor in ovarian cancer (1992) (13)
- A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. (2003) (12)
- A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study. (1995) (12)
- Isolated incisional metastases after intraperitoneal radioactive chromic phosphate therapy for ovarian carcinoma (1991) (12)
- Transperineal templates for brachytherapy treatment of pelvic malignancies--a comparison of standard and customized templates. (1990) (12)
- Superior vena cava syndrome associated with gynecologic malignancy. (1986) (12)
- Fine‐Needle Aspiration in Gynecology: Evaluation of Extrapelvic Lesions in Patients With Gynecologic Malignancy (1985) (11)
- Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies. (1984) (11)
- Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. (1989) (11)
- Surgery for Advanced Ovarian Cancer (1994) (10)
- Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging (1992) (10)
- A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG162). (2004) (10)
- Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. (1996) (10)
- Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging (1991) (9)
- The safety and pharmacokinetics in adult subjects of an intravenously administered 99mTc-labeled 17 amino acid peptide (CYT-379). (1994) (9)
- Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer. (2004) (9)
- Platinum-Resistant and Refractory Ovarian Cancer (2003) (9)
- Combination paclitaxel (Taxol®)–cisplatin vs cyclophosphamide–cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer (1997) (9)
- High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease. (2003) (8)
- Complementary and coordinate markers for detection of epithelial ovarian cancers (1995) (7)
- OVX1 as a marker for early stage endometrial carcinoma (1994) (7)
- Cystoscopy at the Time of Hysterectomy for Benign Indications and Delayed Lower Genitourinary Tract Injury. (2019) (7)
- A statement on abortion by 100 professors of obstetrics: 40 years later. (2013) (7)
- Necrotizing fasciitis in irradiated tissue from diabetic women. A report of two cases. (1991) (7)
- A Gynecologic Oncology Group Phase II Study of Amonafide (NSC 308847) in Epithelial Ovarian Cancer (1993) (6)
- A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus (1991) (6)
- Induction of cytoplasmic progesterone receptor in human endometrial carcinoma transplanted into nude mice. (1984) (6)
- A clinical evaluation of absorbable polydioxanone ligating clips in abdominal and pelvic operations. (1985) (6)
- Venous thromboembolism in gynecologic surgery: Are we any closer to determining an optimal prophylaxis regimen? (2015) (6)
- Computed Tomography-Guided Fine-Needle Aspiration of Retroperitoneal Lymph Nodes in Gynecologic Oncology (1990) (6)
- Serum Progesterone for the Exclusion of Early Pregnancy in Women at Risk for Recurrent Gestational Trophoblastic Neoplasia (1994) (5)
- Percutaneous Nephrostomy in Gynecologic Oncology Patients (1989) (5)
- OVX1 as a marker for early stage endometrial carcinoma. (1994) (5)
- Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. (1998) (5)
- The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. (1992) (5)
- Attitudes Regarding the Use of Hematopoietic Colony-Stimulating Factors and Maintenance of Relative Dose Intensity Among Gynecologic Oncologists (2009) (4)
- Vitamin-B12 deficiency following therapy in gynecologic oncology. (1984) (4)
- Operative morbidity following primary and interval debulking surgery for advanced ovarian cancer. (2004) (4)
- Immunohistochemical expression of TAG‐72 in normal and malignant endometrium: Correlation of antigen expression with estrogen receptor and progesterone receptor levels (1990) (4)
- Thromboprophylaxis for gynecologic surgery: why are we stuck in 1975? (2011) (3)
- Laparoscopic Hysterectomy With Morcellation Versus Abdominal Hysterectomy for Presumed Fibroids: An Updated Decision Analysis Following the 2014 FDA Safety Communications (2017) (3)
- Low-dose heparin in prevention of venous thromboembolism. (1980) (3)
- Pseudoobstruction of the colon complicating choriocarcinoma. (1985) (3)
- Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pegylated liposomal doxorubicin (PLD) pharmacokinetics (PK) in patients with recurrent ovarian cancer. (2011) (2)
- Gynecological cancer management (2009) (2)
- Use of estrogens after treatment for adenocarcinoma of the endometrium (1984) (2)
- Prevention of venous thromboembolic events after gynecologic surgery (Obstetrics and Gynecology (2012) 119, (155-167)) (2012) (2)
- Cellular expression of CA 125 and metastatic potential of endometrial adenocarcinoma (1989) (2)
- Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including chemotherapy, radiation therapy, and surgery (1992) (2)
- A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. A Gynecologic Oncology Group study. (1991) (2)
- Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign Indications. (2018) (2)
- Intraperitoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. (2004) (2)
- The reassessment of ovarian cancer in complete clinical remission: what are our goals? (1994) (2)
- Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. (2012) (2)
- Complications of Disease and Therapy (2012) (2)
- Technetium-99m sulfur colloid (TSC) as a phenotypic probe for predicting pharmacokinetics (PK) and palmar-plantar erythrodysesthesia (PPE) toxicity of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC). (2012) (2)
- Defective release of vascular plasminogen activator in patients with gynecologic malignancies. (1986) (2)
- Palliative surgery for ovarian cancer (2005) (2)
- Screening for Ovarian Cancer in Midlife Women (2011) (1)
- Morbidity and mortality of selective lymphadenectomy in early-stage endometrial cancer (1991) (1)
- Phase I/II results using concurrent hyperthermia, radiotherapy, and chemotherapy for cervix cancer (2001) (1)
- Abstract 2673: Relationship between serum hormone levels and pharmacokinetics (PK) of PEGylated liposomal doxorubicin (PLD) in patients with refractory ovarian cancer (2012) (1)
- Unusual Neoplasms of the Uterus (2009) (1)
- Intraperitoneal chromic phosphorous (P-32) as salvage therapy for persistent ovarian carcinoma (1987) (1)
- Adjuvant radiotherapy following radical hysterectomy for patients with early cervical cancer (1989) (1)
- Fine‐Needle Aspiration Biopsy in Gynecologic Oncology (1992) (1)
- Abdominal vs Minimally Invasive Hysterectomy. (2016) (1)
- Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer (2004) (1)
- Response to Pannucci et al regarding “The Limited Utility of Currently Available Venous Thromboembolism Risk Assessment Tools in Gynecologic Oncology Patients” (2016) (1)
- Combination prophylaxis for thromboembolism prevention among gynecologic oncology patients perioperatively. (2008) (1)
- Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation". (2018) (1)
- A reusable plastic training model for teaching Papanicolaou smear technique. (1987) (1)
- A risk assessment score for postoperative VTE among patients undergoing minimally invasive surgery for gynecologic cancer (2016) (1)
- Immunotherapy of ovarian cancer. (1983) (1)
- Closed retroperitoneal suction drainage following selective lymphadenectomy: Risks and benefits (1992) (1)
- Deep Venous Thrombosis in Gynecologic Surgery (2009) (1)
- Postoperative Venous Thromboembolic Disease: Natural History, Risk Factors, and Prophylaxis (1986) (1)
- Management of patients with gestational trophoblastic neoplasia: experience of the Southeastern Regional Center. (1984) (1)
- Summary of the 2011 Annual Meeting on Women's Cancers (2011) (1)
- Pulmonary embolism after major abdominal surgery in gynecologic oncology. (2006) (1)
- 68 : Combined PET/DCT for Evaluation of Newly Diagnosed Endometrial Cancer: Implications for Radiation Therapy (2006) (0)
- Prognostic nutritional index independently predicts survival in women with epithelial ovarian carcinoma (2017) (0)
- Evaluation and Management of the Adenxal Mass (2009) (0)
- Green's gynecology (2013) (0)
- Laparoscopic hysterectomy with morcellation versus abdominal hysterectomy for presumed fibroids in premenopausal women: a decision analysis (2016) (0)
- The Prevalence and Impact of Invasive Procedures in Women with Gynecologic Malignancies Referred to Hospice Care (2014) (0)
- The Utility of Serum Progesterone for the Exclusion of Early Pregnancy in Patients at Risk for Gestational Trophoblastic Neoplasia (1994) (0)
- Regulation of growth of normal ovarian epithelium and ovarian cancer cell lines by transforming growth factor-β (1991) (0)
- MENOPAUSE MATTERS Screening for Ovarian Cancer in Midlife Women (2011) (0)
- Overexpression and mutation of the p53 oncogene in endometrial adenocarcinoma (1992) (0)
- O r a l T o potecan a s S ingle-Agent S econd-Line C hemotherapy in P atients W ith A dvanced O varian C ancer (2001) (0)
- Match the preventive strategy to the surgery (0)
- Response to Tafur et al regarding “The Limited Utility of Currently Available Venous Thromboembolism Risk Assessment Tools in Gynecologic Oncology Patients” (2016) (0)
- Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation". (2018) (0)
- In Reply. (2016) (0)
- Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer. (2004) (0)
- Clinical Gynecology: Preoperative evaluation and postoperative management (2015) (0)
- Cross-sectional survey of surgical practices among gynecologic oncologists in the United States. (2023) (0)
- Surgical staging in advanced cervical cancer (1989) (0)
- Comparison of dose distributions resulting from standard and custom-designed perineal templates used in interstitial brachytherapy (1989) (0)
- Validity of currently available venous thromboembolism risk scores among gynecologic oncology patients (2016) (0)
- Ovarian Cancer in Pregnancy (1985) (0)
- High‐dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer (1991) (0)
- Prevention and Treatment of Deep Vein Thrombosis in Gynecologic Surgery (1998) (0)
- Secondary cytoreductive surgery did not improve survival in women with advanced ovarian cancer (2005) (0)
- Chapter 17 – Complications of Disease and Therapy (2007) (0)
- Recurrent gestational neoplasia: Experience of the Southeastern Trophoblastic Disease Center (1988) (0)
- A practical approach to low-molecular-weight heparin in gynecologic surgery (2003) (0)
- Low molecular weight heparins in the prophylaxis and treatment of perioperative deep vein thrombosis (1998) (0)
- Technetium-99m sulfur colloid (TSC) as a phenotypic probe for the pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC). (2011) (0)
- Ask the experts. (2001) (0)
- Family planning. (1968) (0)
- Venous thromboembolic disease in obstetrics and gynecology: Prevention, diagnosis, and treatment (1989) (0)
- Cost-Effectiveness of Laparoscopic Hysterectomy With Morcellation Compared to Abdominal Hysterectomy for Presumed Benign Leiomyomata. (2015) (0)
- Risk of venous thromboembolism in minimally invasive versus open hysterectomy for endometrial cancer (2016) (0)
- Obesity is associated with worse quality of life in women with gynecologic malignancies: An opportunity for improving patient-centered outcomes (2014) (0)
- Role of PET scanning in the detection and management of recurrent cervical cancer (2002) (0)
- Randomized trial of intraperitoneal chronic phosphate therapy versus observation following negative second-look laparotomy for stage III ovarian carcinoma: a gynecologic oncology group study (2002) (0)
- A practical approach to using low-molecular-weight heparin in gynecologic surgery patients (2003) (0)
- Overexpression of HER-2/neu in endometrial carcinoma is associated with poor prognosis (1991) (0)
- The impact of outpatient versus inpatient referrals to hospice (2014) (0)
This paper list is powered by the following services:
